New drug duo aims to halt Tough-to-Treat breast cancer

NCT ID NCT06365788

Summary

This study is testing whether combining two existing drugs, bicalutamide and abemaciclib, can help control a hard-to-treat form of advanced breast cancer. It is for women whose cancer has a specific marker (androgen receptor positive) and has worsened after at least one prior treatment. The main goal is to see if the combination can stop the cancer from growing for at least 16 weeks.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST NEOPLASMS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Antwerp University Hospital

    NOT_YET_RECRUITING

    Antwerp, Belgium

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Ghent University Hospital

    RECRUITING

    Ghent, Belgium

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Jessa Ziekenhuis

    RECRUITING

    Hasselt, Belgium

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • University Hospital Brussels

    RECRUITING

    Brussels, Belgium

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • University Hospitals Leuven

    RECRUITING

    Leuven, Belgium

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • ZAS Augustinus

    RECRUITING

    Antwerp, 2610, Belgium

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.